The use of psilocybin (magic mushrooms) for therapeutic purposes gains traction Last month, the NBA and its players association reached a tentative deal that the league would no longer test players for marijuana. Indeed, the NBA is lifting its ban on marijuana in the new collective bargaining agreement. Meanwhile, the NFL and its players agreed
A few weeks ago, we held a webinar about ketamine regulation and the future of psychedelic medicine (for a recording, click here). At the time, there were big changes on the horizon for ketamine telehealth. In the last few weeks, there have been a few pretty significant developments that merit some attention. For some background,
In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that many of the same trends we have seen over the last few years in ketamine therapy will apply to these
Over the last year and change, I’ve written quite a bit about how the ketamine telehealth industry was in store for a rude awakening when the COVID-19 public health emergency (PHE) declaration ended. My most recent post, entitled “Bad News for Ketamine Telehealth” predicted an imminent shakeup in the industry due to the looming end
Last summer, my colleague, Ethan Minkin, published a post entitled “Utah Ketamine Clinics Face New Patient Monitoring Law.” The law in question applied a host of new requirements on anesthesia or sedation providers, which created a series of hurdles for ketamine clinics. A few weeks ago, a Utah state legislator submitted a bill that would
Earlier this week, President Joe Biden’s administration made an announcement that signals potential bad news for the ketamine telehealth industry. Effective May 11, 2023, the federal COVID-19 public health emergency (PHE) declaration will end. This is likely to plunge the entire ketamine telehealth industry into chaos in the coming months. If you are unfamiliar with
Last week, we presented a psychedelics webinar entitled “How to Protect Your Psychedelics Business.” The panelists were Paul Coble, me (Griffen Thorne from our Los Angeles office), and Graham Pechenik of Calyx Law in San Francisco. In the webinar, we presented on business law and intellectual property issues that will affect new psychedelics businesses in
In early 2020, the United States Department of Health and Human Services (DHHS) declared a public health emergency (PHE) due to the COVID-19 pandemic. DHHS extended the PHE numerous times over the last few years, most recently on July 15, 2022 for a period of 90 days. The PHE will expire on October 13, 2022
In 2023, Oregon will have a regulated psilocybin market. Colorado voters will have a chance to vote on something similar this fall (although Initiative 58 would not take effect until 2024). Other than that, not a single other state has any form of psychedelic regulation in the works. Last week, an attempt to simply decriminalize
Earlier this year, Utah passed a law that will directly impact ketamine clinics. The new law is entitled “Anesthesia and sedation requirements – Unprofessional conduct – Whistleblower protection.” Ut. St. § 58-1-510. The new law is effective as of May 4, 2022, but the implementing regulations have been passed or implemented yet. We believe that
